Skip to main content

Articles By Eric Dein, MD

iv.infusion.jpg

Can "Ultra-low" dose Rituximab work for RA?

By Eric Dein, MD
11 November 2021

The REDO trial presented data in abstract 1443 in an oral presentation challenging how low we can go with rituximab for rheumatoid arthritis. Their study randomized 118 patients with rheumatoid arthritis to 1000 mg, 500 mg, and "ultra-low" dose 200 mg.

Read Article
Slot,Machine,Jackpot

After failing a JAK inhibitor, can you still hit a JAK-pot?

By Eric Dein, MD
08 November 2021

Januse kinase (JAK) inhibitors are targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs) that have risen in popularity as earlier treatment options for rheumatoid arthritis.

Read Article
Sjogren_syndrome_salivary%20bx%282%29.jpg

Can the Focus Score predict Lymphoma in Sjogren’s syndrome?

By Eric Dein, MD
08 June 2021

Patients with Sjogren’s syndrome are nearly 19 times more likely to develop lymphoma, so identifying factors that impact this risk development is a major goal in caring for this disorder.

Read Article
Lupus.right_.jpg

Is Rituximab and Belimumab the Combination to Beat Lupus?

By Eric Dein, MD
04 June 2021

On day 2 of EULAR conference, Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab. B cell depletion with rituximab is common treatment for refractory SLE, though real-world data for rituximab has been uncertain. It is known that B-cell activating factor (BAFF) levels can increase after rituximab, which can lead to disease flares. Using belimumab, a human monoclonal antibody inhibiting BAFF, could be a potential therapeutic option after rituximab infusions. 

Read Article
steroids.prednisone.pills_.jpg

Mortality in Low Dose Prednisone

By Eric Dein, MD
08 December 2020

Upon release of the new ACR 2020 Pharmacologic Treatment Recommendations for the Management of Rheumatoid Arthritis, many practitioners were surprised that the new guidelines recommended against glucocorticoid initiation at disease onset.

Read Article
doctor.coat_.jpg

Outcomes Switching to Monotherapy: SEAM-RA Trial

By Eric Dein, MD
07 November 2020

Combination therapy with biologic and conventional DMARDs can be highly effective at inducing remission in patients with RA. Once controlled, patients are often interested in stopping combination drug therapy due to concerns related to medication burdens, side effect profiles, or safety. 

Read Article
×